Satellos shares adult TRAILHEAD data on Duchenne pill SAT-3247 ahead of a potentially pivotal BASECAMP readout in children by year-end.
July 8, 2026 06:30 AM EDT
Satellos gives early look at Duchenne pill in adults ahead of key data in children
Lei Lei Wu
News Reporter
Satellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children …
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see…
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
